HLB Pep Co., Ltd. Overview
Key Facts
| Item | Detail | Source |
|---|---|---|
| Current legal name | HLB Pep Co., Ltd. (HLB펩 주식회사) | Biospectator, 1 Apr 2025; Dealsite, 1 Apr 2025 |
| Former name | Anygen Co., Ltd. (애니젠 주식회사) | Biospectator; Hankyung, 31 Mar 2026 |
| Origin of former name | Taken from Samsung's "Anycall" handset brand at founding. A promised Samsung investment was later withdrawn because of investment regulations. | Hankyung, 31 Mar 2026 |
| Founded | 2,000 | PatSnap; CB Insights; company IR deck, May 2025 |
| Founder | Dr. Kim Jae-il, then a professor at GIST's School of Life Sciences | Hankyung, 31 Mar 2026 |
| Incorporation jurisdiction | Republic of Korea | Investing.com profile |
| Headquarters | Gwangju, South Korea. | Investing.com; Asia Economy, 30 Jun 2026 |
| Exchange / ticker | KOSDAQ (Korea Exchange) / 196300 | KRX data via StockHub |
| Listing route and date | Technology-growth special listing (기술특례). The Korea IR Council report gives December 2016; Aju News gives November 2016. | Korea IR Council, 26 Jun 2024; Aju News, 8 Dec 2021 |
| Par value | KRW 500 per share | Aju News, 8 Dec 2021 |
| ISIN / CUSIP | check digit not confirmed). No CUSIP; not US-listed. | — |
| Fiscal year end | 31 December | Butler (DART aggregation) |
| Employees (latest and 3-year trend) | — | — |
| Auditor | — | — |
| Market capitalisation | About KRW 41.0bn at KRW 4,320/share (latest Butler quote). About KRW 44.3bn at KRW 4,665 on 12 Oct 2026 (StockHub). | Butler; StockHub |
| Implied shares outstanding | About 9.5 million (derived: market cap ÷ share price) | Derived |
| Controlling shareholder | HLB Genex Co., Ltd. (HLB제넥스) and related parties: 42.46% after an August 2026 report, down from 42.70% | DART large-shareholding report, 20 Aug 2026, via StockHub |
| Ultimate group | HLB Group, chaired by Jin Yang-gon. HLB Pep is the group's 11th listed affiliate. | Smart Today, 10 Mar 2025 |
| Website | Legacy: http://www.anygen.com. | Input list |
| Management structure | Co-CEO structure from 31 March 2025: Shim Kyung-jae (management) and Kim Jae-il (business). By March 2026 Kim Jae-il was described as CTO. | Dealsite, 1 Apr 2025; Hankyung, 31 Mar 2026 |
| Listing status flag | Designated an administrative-issue stock (관리종목) in March 2025. The trigger was pre-tax continuing-operations loss (법차손) above 50% of equity. | Bizwatch, 31 Mar 2025; Dailypharm |
HLB Pep, formerly Anygen, is Korea's pioneer specialist in synthetic peptides.
Manufacturing base: It says it is the only Korean company with peptide-dedicated GMP facilities for active pharmaceutical ingredients (APIs). It runs two plants:
-
Jangseong, South Jeolla. GMP-certified in 2011, the first in Korea.
-
Osong, North Chungcheong. GMP-certified in 2020.
Scale and revenue: It makes more than 5,000 peptides a year across GMP and non-GMP grades. Revenue comes from custom and research peptides, CDMO work, generic peptide APIs (ganirelix, vasopressin) and a chemical library.
Pipeline: A long-dated drug pipeline spans oncology, infection, metabolic disease and inflammation.
Ownership and funding: HLB Group took control in March 2025 through about KRW 60bn of equity and convertible bond (CB) financing. This ended years of liquidity strain and a minority-shareholder dispute.
Post-acquisition strategy: The company is now pursuing:
-
international API and CDMO sales (Japan, US, Hong Kong);
-
a peptide cosmetics brand (LABSENN);
-
a GLP-1/glucagon dual-agonist obesity programme;
-
a radiopharmaceutical collaboration.
Financial position: The business is still small (FY2025 revenue KRW 5.0bn) and loss-making. Its valuation is tied to HLB Group sentiment and to a KRW 30bn CB overhang.
What the Company Does
HLB Pep designs, synthesises, purifies and supplies peptides — chains of roughly 2 to 50 amino acids — for pharmaceutical, research, cosmetic and industrial uses. Founder Kim Jae-il is credited with helping define that size range in the field (Hankyung, 31 Mar 2026). The business has five lines.
-
Peptide APIs (GMP). Manufactures pharmaceutical-grade peptide APIs in MFDS-certified GMP plants.
-
Ganirelix (an infertility drug API) is supplied domestically. Its product approval was obtained in 2023 (Korea IR Council, 26 Jun 2024).
-
Vasopressin (an antidiuretic hormone API) was registered on Korea's DMF system in December 2025 and on the US FDA's DMF system in July 2026 (Biospectator, Dec 2025; Finance Scope, 27 Jul 2026; Asia Economy, 20 Aug 2026).
-
-
CDMO. Contract process development and manufacturing for drug developers. Korean peptide drug developers that need domestic GMP supply generally use the company, as Hankyung's March 2026 profile notes. Its first disclosed overseas definitive CDMO contract was signed with Japan's PeptiGrowth on 30 June 2026.
-
Research, custom and catalogue peptides. Non-GMP peptides for academia and industry R&D.
- Q2 2026 revenue split (Butler, DART-based): CDMO and research peptides 91%, chemical library 9%.
-
Cosmetic peptide materials and the LABSENN brand.
-
Supplies peptide ingredients.
-
Launched its own derma brand, LABSENN, in 2026. The core ingredient is the patented CMPEP™, a combination of curcumin peptide and marine peptide.
-
First export: four LABSENN products to Romania, announced 7 October 2026.
-
-
Proprietary drug discovery. AGM-series candidates in oncology, antiviral, antibacterial, metabolic and inflammatory indications. Most are preclinical; AGM-130 reached Phase 1.
The Company's Own Description
In its May 2025 IR deck, the company calls itself Korea's leading peptide materials developer. It sets out three growth engines:
-
strengthening the core API and CDMO business;
-
building a cosmetics "cash cow";
-
new drug development as "upside potential".
At the May 2025 HLB Forum, CEO Shim Kyung-jae said the company's technology had been undervalued because of past management issues, and that HLB's acquisition had resolved its liquidity problems (Biospectator, 22–23 May 2025).
Independent Characterisation
On the evidence available, HLB Pep is best described as a sub-scale peptide CDMO and API supplier with a venture-style pipeline attached.
Revenue trend: Revenue fell from KRW 10.3bn in FY2021 to KRW 5.0bn in FY2025.
Profitability: Operating losses were KRW 4.3–7.3bn a year in FY2022–FY2025 — a cost base well above revenue.
Disclosed sales mix: Dominated by CDMO and research peptides, so commercial API sales of ganirelix and vasopressin are not yet a separately visible revenue driver.
Strategic value: Its value to HLB Group lies in three things:
-
domestic peptide GMP capacity, which is scarce;
-
optionality on the GLP-1 and peptide-drug supply chain;
-
a platform for group-wide peptide and radiopharmaceutical projects.
Revenue Model
| Revenue type | Description | Disclosed weight |
|---|---|---|
| Product / contract manufacturing | CDMO, custom and research peptides, GMP APIs | 91% of Q2 2026 revenue (CDMO and research peptides combined) |
| Product (catalogue) | Chemical library | 9% of Q2 2026 revenue |
| Consumer products | LABSENN cosmetics; launched 2026, first export October 2026 | — |
| Licensing / milestones | No out-licensing revenue identified in sources reviewed | Not identified |
| Subscription | Not applicable | — |
Value Chain Position
The company sits upstream as:
-
a peptide synthesis and purification specialist, using solid-phase (SPPS) and solution-phase (SPS) synthesis (IntuitionLabs profile);
-
a GMP API manufacturer;
-
a CDMO for drug developers.
It is also building:
-
a downstream presence in finished consumer cosmetics (LABSENN);
-
early-stage new drug discovery.
Customer Types and End-Markets
| Customer type | Examples / evidence |
|---|---|
| Domestic pharma and biotech drug developers | Novacell Technology (described as a long-standing partner on national drug development projects); Cellivery (KRW 0.8bn preclinical supply contract, Sept 2021) |
| Overseas biotech | PeptiGrowth (Japan), CDMO contract June 2026 |
| Overseas distributors | NovaBridge (Hong Kong), sales and business-development MOU June 2026 |
| Research institutions and universities | Research and catalogue peptides; joint work with GIST |
| Finished-dose pharma | Ganirelix and vasopressin API buyers. Named customers not disclosed. |
| Cosmetics buyers and consumers | Romanian buyer for LABSENN (October 2026); domestic consumers |
End-markets served: pharmaceuticals (peptide therapeutics, including the obesity/GLP-1 class, infertility and critical care); biomedical research; regenerative medicine and cell culture (functional peptides via PeptiGrowth); cosmetics.
Strategy
Stated Corporate Strategy (Paraphrased Themes)
The May 2025 IR deck and the 22 May 2025 HLB Forum set out three pillars:
-
Strengthen core API and CDMO and expand overseas (Japan, US).
-
Build a cosmetics cash cow using peptide materials.
-
Pursue new drug "upside", especially obesity (GLP-1/glucagon dual agonist), then oncology.
Management also pointed to group collaboration — using HLB's marketing and sales capabilities, a point HLB Genex's CEO made at the May 2025 joint IR.
Initiatives Announced in the Last 24 Months
| Initiative | Category | Date | Detail |
|---|---|---|---|
| Rename to HLB Pep; co-CEO structure | Governance | Mar–Apr 2025 | New management separates business and management roles |
| FDA cGMP pursuit (ganirelix) | Regulatory / market access | 2,025 | Aimed at US sales |
| Facility investment and CDMO reorganisation | Operations | 2,025 | Described as large-scale capex and business reorganisation (Biospectator, Dec 2025) |
| Vasopressin DMF (Korea, then US FDA) | Product / regulatory | Dec 2025; Jul 2026 | Global market cited at about USD 2.4bn (company) |
| Curcumin-based cosmetics → LABSENN | New business | Planned 2025; launched 2026 | Four products; exported to Romania October 2026 |
| Oncology pipeline refocus | R&D | Dec 2025 | Management said it was resetting pipeline direction toward oncology |
| RayMed RPT co-development | R&D partnership | Jan 2026 | AGM-330 peptide ligand plus dosimetry/AI platform |
| Novacell MOU | R&D / supply | Feb 2026 | Oral UC peptide immunotherapy; priority co-development right |
| PeptiGrowth CDMO | Commercial | May–Jun 2026 | First overseas definitive CDMO contract |
| NovaBridge MOU | Sales channel | Jun 2026 | Overseas research and industrial peptide sales |
| Dual-agonist obesity programme | R&D | Ongoing (national project) | Long-acting injectable platform |
| Automation and process efficiency at Osong | Operations | 2,026 | Large-scale synthesis and high-difficulty purification capabilities |
Other Strategy Items
Medium-term financial targets: No quantified revenue or margin guidance was identified in sources reviewed. Management statements are qualitative; for example, CEO Shim said in Dec 2025 that 2026 would mark the start of full-scale growth.
Sustainability / ESG commitments: None identified.
Cost programmes with targets: None identified.
Products & Services
Peptide APIs (GMP)
| Product | Description | Target customer | Status / latest milestone | Source |
|---|---|---|---|---|
| Ganirelix | GnRH antagonist peptide API used in infertility treatment | Korean finished-dose pharma; potential US buyers | Korean product approval 2023; supplied domestically. FDA cGMP review described as forthcoming in July 2025. | Korea IR Council; Biospectator, 16 Jul 2025 |
| Vasopressin | Antidiuretic hormone API. Promotes renal water reabsorption and constricts blood vessels; used as an adjunct vasopressor in critically ill patients. | Global sterile injectables makers | Korean DMF about December 2025 (company says domestic first). US FDA DMF July 2026. | Biospectator, Dec 2025; Finance Scope, 27 Jul 2026 |
| Other generic peptide APIs | Company states "GMP peptides" and "generic peptides" as service lines | Pharma | — | CB Insights; Investing.com |
The company cited a global vasopressin market of about USD 2.4bn in 2025 (Biospectator, Dec 2025, citing the company).
CDMO and Custom Peptides
| Offering | Description | Target customer | Notes |
|---|---|---|---|
| Peptide CDMO | Process development, scale-up, GMP manufacture for clinical and commercial supply | Drug developers in Korea; Japan, US and other overseas targets | Definitive contract with PeptiGrowth (Japan) for next-generation synthetic growth-factor and cytokine peptides used in cell culture and regenerative medicine (30 Jun 2026) |
| Custom peptides (GMP and non-GMP) | Made-to-order synthesis and purification using SPPS and SPS | Pharma, biotech, academia | More than 5,000 peptides produced a year (CEO, May 2025) |
| Catalogue / research peptides | Standard research-grade peptides | Research labs | Overseas distribution supported by NovaBridge (Hong Kong), June 2026 |
| Functional peptides | High-complexity peptides for cell culture and regenerative medicine | Biotech; cell-therapy developers | Via the PeptiGrowth partnership |
Chemical Library
| Offering | Description | Share of revenue |
|---|---|---|
| Chemical library | Compound library supply. | 9% of Q2 2026 revenue |
Cosmetics (LABSENN and Ingredients)
| Product | Launch | Key features (company-reported) | Source |
|---|---|---|---|
| LABSENN Peptide Calming Serum | H1 2026 | Aimed at inflammatory skin conditions such as acne | Asia Economy, 20 May 2026; Finance Scope, 7 Oct 2026 |
| LABSENN Peptide Repair Micro Bubble Essence | 28 Jul 2026 | CMPEP™ patented ingredient; cream-in-essence micro-bubble format; 20 peptides plus collagen, adenosine, 8 hyaluronic acids and ceramide. Company-reported human-application test results: elasticity +10.89%, soothing +26.91%, barrier +12.65%. | Dailypharm; Asia Economy, 28 Jul 2026 |
| LABSENN Peptide Repair Hydra Sunscreen | 2,026 | Part of the 4-product export set | Finance Scope, 7 Oct 2026 |
| LABSENN Peptide Repair Barrier Cream | 2,026 | Part of the 4-product export set | Finance Scope, 7 Oct 2026 |
| CMPEP™ (ingredient) | — | Patented combination of curcumin (anti-inflammatory/antioxidant) with seaweed-derived marine peptides | Asia Economy, 7 Oct 2026 |
| In development | — | New anti-inflammatory peptide materials; scalp-care and hair-loss prevention products | Asia Economy, 7 Oct 2026 |
Proprietary Drug Pipeline
| Code | Indication / mechanism | Latest reported stage | Source / notes |
|---|---|---|---|
| AGM-130 | Triple-negative breast cancer; first-in-class | Phase 1 (reported 2017 and in current third-party profiles). | Dealsite, 2017; Investing.com; StockHub |
| AGM-330 | Tumour-targeting peptide that binds nucleolin over-expressed on cancer cell membranes | Research. Basis of the RayMed RPT collaboration (Jan 2026). | Biospectator, 5 Jan 2026 |
| AGM-331 | Anticancer | Preclinical | Investing.com |
| AGM-380 | Viral infection | Preclinical | Investing.com |
| AGM-290 | Multidrug-resistant bacterial infection | Preclinical | Investing.com |
| AGM-212 | Type 2 diabetes | Preclinical | Investing.com; Dealsite, 2017 |
| AGM-217 | Type 2 diabetes and obesity | Preclinical | Investing.com |
| AGM-260 | Ulcerative colitis | Preclinical | Investing.com |
| AGM-251 | Neuropathic pain | Preclinical (2017). | Dealsite, 2017 |
| GLP-1/glucagon dual agonist | Obesity. Long-acting injectable platform; national research project. | Development. In April 2025 management had described an oral formulation goal. | Financial News; Finance Scope, 26 Jun 2026; Dealsite, 1 Apr 2025 |
| AGM-330-based RPT (with RayMed) | Radiopharmaceutical therapy. HLB Pep supplies the targeting peptide; RayMed handles isotope design, dosimetry and AI-based non-clinical evaluation. | Candidate design / preclinical | Biospectator, 5 Jan 2026 |
| Novacell collaboration | Peptide immunotherapies, including an oral ulcerative colitis treatment. HLB Pep is raw-material supplier with priority negotiation right for co-development. | MOU (Feb 2026); definitive agreement pending | Biospectator, 23 Feb 2026 |
Financial Narrative
Income Statement (Chartable)
Basis: Butler (DART aggregation).
Notes:
- Butler states FY2025 revenue fell 20.3% YoY; the derived figure is -19.4%. The gap reflects rounding of the KRW 100M-unit source data.
Third-Party Ratio Snapshots (Conflicting)
Implied book equity is about KRW 23bn (derived: KRW 41.0bn market cap ÷ 1.78x P/B). This is a market-data inference, not a reported figure.
Commentary on Trends, Inflections and Drivers
Revenue erosion through 2023. Revenue fell 46% between FY2021 and FY2023, from KRW 10.3bn to KRW 5.6bn.
-
Contemporary sources point to two causes:
-
chronic funding constraints;
-
a management dispute with minority shareholders, which began around May 2023 and was followed by litigation into January 2024 (IB Tomato; Dealsite).
-
-
Management later described the company as undervalued because of these management issues (CEO Shim, May 2025).
Partial recovery in FY2024, renewed decline in FY2025.
-
FY2024 revenue recovered to KRW 6.2bn.
-
FY2025 revenue fell to KRW 5.0bn even though HLB's capital arrived in March 2025.
-
Management said in December 2025 that 2025 had been spent on capex, CDMO reorganisation and business restructuring (Biospectator, Dec 2025). This suggests a transition year in which commercial output was not yet prioritised.
Widening operating loss in FY2025.
- The operating loss rose to KRW 7.3bn, the largest in the five-year window.
Net income inflection in FY2025.
-
The net loss narrowed sharply to KRW 0.6bn against a KRW 7.3bn operating loss.
-
That implies about KRW 6.7bn of net non-operating gains. Possible sources include gains on CB/derivative revaluation, finance income or asset disposals.
-
This matters for listing status. A small pre-tax loss relative to the post-recapitalisation equity base would help the company stay below the 50% 법차손 threshold that triggered the March 2025 designation.
2026 trajectory.
-
Bullstory's 50.9% revenue growth figure, if it reflects TTM to June 2026, implies a meaningful H1 2026 recovery.
-
The Q2 2026 mix (91% CDMO and research peptides) indicates the core service business is still the driver, not APIs or cosmetics.
-
The H1 2026 semi-annual report (filed 13 Aug 2026) should be reviewed for confirmation.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Group Structure
| Level | Entity | Relationship |
|---|---|---|
Group apex | HLB Co., Ltd. (KOSDAQ: 028300) / Chairman Jin Yang-gon | Group leadership |
Intermediate parent | HLB Genex Co., Ltd. (formerly Genofocus; industrial enzymes) | Largest shareholder of HLB Pep following the April 2025 restructuring |
Listed company | HLB Pep Co., Ltd. (KOSDAQ: 196300) | Subject company |
Subsidiaries of HLB Pep | None identified in sources reviewed. | — |
Segment / Product Line Details
| Segment / product line (as reported) | Contents | Share of Q2 2026 revenue (%) |
|---|---|---|
CDMO, research peptides | GMP/non-GMP custom peptides, CDMO services, research and catalogue peptides; APIs appear to be included | 91 |
Chemical Library | Chemical library sales | 9 |
Revenue by Segment
| Segment | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Total revenue (KRW Bn) | 5.6 | 6.2 | 5.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (KRW Bn) | 10.3 | 8.7 | 5.6 | 6.2 | 5.0 |
Operating income (KRW Bn) | -0.3 | -4.3 | -6.7 | -5.4 | -7.3 |
Net income (KRW Bn) | -1.7 | -6.2 | -9.1 | -6.8 | -0.6 |
Revenue growth YoY (%, derived) | 0 | -15.5 | -35.6 | 10.7 | -19.4 |
Operating margin (%, derived) | -2.9 | -49.4 | -119.6 | -87.1 | -146.0 |
Net margin (%, derived) | -16.5 | -71.3 | -162.5 | -109.7 | -12.0 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021–FY2025 |
|---|---|
Revenue CAGR (%, derived) | -16.5 |
Financial Analysis
| Item | Status |
|---|---|
Pre-tax income | Relevant to the 법차손 test. |
EPS (basic/diluted) | Loss-making in all five years. |
Dividends per share | Zero. No dividend identified; StockHub shows 0.00% yield. |
Financial Analysis — ROE
| Indicator | Butler | StockHub | Bullstory | Comment |
|---|---|---|---|---|
ROE (%) | -13.9 | -2.5 | -8.8 | Different periods and methods; none verified against DART |
P/B (x) | 1.78 | 1.70–1.82 | — | Consistent range |
Debt-to-equity (부채비율, %) | — | — | 74.1 | — |
Revenue growth (%, TTM basis presumed) | — | — | 50.9 | — |
Net margin (%, TTM presumed) | — | — | -37.6 | — |
Financial Analysis — Equity raised in HLB acquisition
| Item | Amount | Date / status | Source |
|---|---|---|---|
Equity raised in HLB acquisition | KRW 20bn third-party allotment: KRW 15bn HLB affiliates, KRW 5bn financial investors | Approved 10 Mar 2025 | Asia Economy, 11 Mar 2025; Dealsite |
CBs issued in HLB acquisition | KRW 40bn: KRW 5bn HLB affiliates, KRW 35bn financial investors | March 2025 | Asia Economy, 11 Mar 2025; Smart Today |
Outstanding CBs | KRW 30.0bn | As of 31 Mar 2026 | Bizwatch, 14 Jul 2026 (FSS data) |
Investor put option window | KRW 30.0bn eligible for early redemption | October 2026 | Bizwatch, 14 Jul 2026 |
3rd-series CB conversion request | — | 12 Aug 2026 | Butler filing list |
Decision to acquire own CBs before maturity | — | 8 Sep 2026 (major matters report) | Butler filing list |
Dimension Details
| Dimension | Status |
|---|---|
Geographic split (domestic vs export) for three years | In May 2025 the CEO said the business had so far been confined to the domestic market, which implies predominantly Korean revenue. |
Country-level revenue | Not publicly identified |
Markets
| Market | Initiative | Date | Revenue impact |
|---|---|---|---|
Japan | CPHI Japan participation; PeptiGrowth MOU, then definitive CDMO contract | Jul 2025; May–Jun 2026 | Contract value not disclosed |
United States | Ganirelix FDA cGMP review (pending as of Jul 2025); vasopressin FDA DMF | 2025; Jul 2026 | No US sales figures disclosed |
Hong Kong / North America | NovaBridge MOU for overseas sales and business development | 26 Jun 2026 | — |
Europe (Romania) | LABSENN 4-product export | 7 Oct 2026 | — |
Asia, South America | LABSENN export talks under way | Oct 2026 | — |
“—” = not publicly disclosed.
Share Price History
| Date | Price (KRW) | Context | Source |
|---|---|---|---|
8 Dec 2021 | 16,600 | Market cap about KRW 93bn | Aju News |
circa 2023 (month reported as September) | 23,650 (peak) | Before Atinum's share sales | IB Tomato |
11 Mar 2025 | 11,890 | After HLB acquisition news; two prior upper-limit sessions | Asia Economy |
29 Jun 2026 | 4,605 | Before the PeptiGrowth announcement | Asia Economy |
10 Jul 2026 | 4,010 | Down 14.32% on the HLB CRL | Asia Economy |
23 Jul 2026 | 3,885 | — | Bullstory |
12 Oct 2026 | 4,665 | Down 10.63% on the day | StockHub |
Latest (Oct 2026) | 4,320 | Market cap about KRW 41.0bn | Butler |
52-week range | 3,510 – 9,530 (StockHub) / 3,510 – 9,990 (Bullstory) | Sources differ on the high | StockHub; Bullstory |
Valuation Multiples
| Multiple | HLB Pep | Comment |
|---|---|---|
P/B | 1.70–1.82x | StockHub / Butler |
P/S (trailing FY2025, derived) | 8.2x | KRW 41.0bn ÷ KRW 5.0bn |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | None. StockHub shows 0 reports. Historical coverage: Kiwoom (2017), Hyundai Motor Securities comment (2021), Korea IR Council sponsored report (Jun 2024). |
Dividend history and policy | No dividends identified (0.00% yield) |
Buyback authorisations | None identified. Insider purchases by CEO and group chairman in 2026. |
Credit ratings (Moody's / S&P / Fitch) | Not publicly disclosed (unrated) |
Debt maturity profile | Acquisition CBs: KRW 30.0bn outstanding (Mar 2026); investor put exercisable October 2026; company resolved early acquisition on 8 Sep 2026. |
Analyst Conclusions
Management Guidance and Consensus
| Item | Status |
|---|---|
| Quantitative guidance | None identified |
| Qualitative guidance | Management framed 2025 as a restructuring year and 2026 as the start of full-scale growth (Biospectator, Dec 2025). Global sales growth targeted with Japan and the US as priority markets (CPHI Japan, Jul 2025). |
| Consensus estimates | None (no sell-side coverage) |
Bull Case
-
API commercialisation. US FDA DMF registration for vasopressin (Jul 2026) and pursuit of FDA cGMP for ganirelix could turn into US API orders. Against a revenue base of only KRW 5.0bn, a few commercial API contracts would move growth materially.
-
Scarcity value amid GLP-1 demand. As the only Korean peptide-dedicated GMP API maker, HLB Pep is the natural domestic partner for Korean peptide developers and a beneficiary of GLP-1-driven capacity tightness. Japan's PeptiGrowth contract validates its supplier-audit readiness.
-
Group support caps downside. HLB Group holds 42.46%, and both the chairman and CEO bought shares in 2026. The group has also shown a pattern of using affiliate funds to absorb CB redemptions elsewhere in the group (Smart Today, Aug 2025). This reduces near-term solvency risk around the October 2026 put.
Bear Case
-
No proof of commercial traction. Revenue fell 19.4% in FY2025 (derived) despite KRW 60bn of fresh capital, and operating losses widened to KRW 7.3bn. Proof of a commercial turnaround has not yet appeared in audited numbers.
-
CB overhang larger than revenue. KRW 30bn of CBs exceeds six times FY2025 revenue. Redemption consumes cash; conversion dilutes shareholders. A sector-wide CB put wave is under way (Dailypharm, Sep 2026).
-
Price driven by group events. The stock trades on HLB Group events rather than its own fundamentals (-14.32% on the 10 Jul 2026 CRL). Listing-status risk under KOSDAQ 법차손 and revenue rules persists if losses do not narrow.
Catalysts and Monitorables (Next 12 Months)
-
CB resolution. Amount acquired under the 8 Sep 2026 decision; remaining CB balance; funding source (internal cash vs group support vs new financing).
-
H1 2026 results. Confirm the TTM growth implied by third-party data and the revenue mix by product line.
-
Listing status. Confirm whether the administrative-issue designation was lifted after FY2025 results. Check the FY2025 법차손/equity ratio.
-
FY2026 annual results (Mar 2027). First full year post-restructuring.
-
FDA milestones. Ganirelix cGMP outcome; first US vasopressin API orders.
-
CDMO pipeline. PeptiGrowth production ramp; further overseas CDMO contracts (NovaBridge leads).
-
R&D. Obesity dual-agonist preclinical data or IND timing (the 2024 report cited a 2026 Phase 1 IND target); RayMed RPT candidate selection; Novacell definitive agreement.
-
LABSENN. Sell-through and additional export markets.
-
Group events. HLB rivoceranib resubmission; IR Day (15 Oct 2026) disclosures.
Analyst Verdict
HLB Pep is a strategically interesting but financially fragile asset.
What the market is paying for. Its core proposition is that it is Korea's only dedicated peptide GMP API manufacturer, with more than two decades of synthesis know-how. That proposition gained relevance as GLP-1 therapies made peptide capacity scarce, and it explains why HLB Group paid about KRW 60bn in equity and CBs for control in March 2025.
What the reported numbers show. On reported figures, the operating business has not yet responded to the recapitalisation:
-
revenue of KRW 5.0bn in FY2025 is below every year from FY2021 to FY2024 except FY2023;
-
the operating loss widened to KRW 7.3bn;
Progress in 2026. The second-year agenda shows tangible progress:
-
a US FDA DMF for vasopressin;
-
a definitive CDMO contract with a Japanese biotech after a supplier audit;
-
a Hong Kong distribution partner;
-
a first consumer export.
These are the right building blocks, but none has yet been quantified in revenue.
Valuation. The equity trades at about 8x trailing sales and about 1.8x book. That is a premium for a loss-making micro-cap, and it rests on group affiliation and peptide-sector optionality rather than earnings.
Near-term swing factor. The CB structure decides the near term. About KRW 30bn was eligible for put in October 2026, and the company resolved to acquire CBs early in September. How that is funded — internal cash, group money or new paper — will shape dilution and solvency perceptions.
Conclusion. HLB Pep is a speculative, event-driven holding whose investment case depends on converting regulatory filings into recurring API and CDMO revenue within the next 12–18 months. Monitoring priorities, in order:
-
CB settlement;
-
H1 2026 and FY2026 revenue mix;
-
listing-status confirmation;
-
first US API orders.
Absent visible revenue inflection by FY2026 results, the stock is likely to remain a proxy for HLB Group sentiment rather than a standalone peptide CDMO story.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | Education | Source |
|---|---|---|---|---|---|
Shim Kyung-jae (심경재) | CEO (co-CEO, management) | Since 31 Mar 2025 | External affairs at Doosan E&C and Samsung S1; joined HLB Group in 2019 as communications team leader; CEO of HLB Neurotobe from 2024 | Business, Chung-Ang University | Dealsite, 1 Apr 2025 |
Kim Jae-il (김재일) | Founder; co-CEO (business) from Mar 2025; described as CTO by Mar 2026 | Founder (2000) | Researcher at Mitsubishi Kasei Institute of Life Sciences (Japan); assistant professor at the University of Tokyo; professor at GIST | PhD in biochemistry, University of Tokyo | Dealsite, 1 Apr 2025; Hankyung, 31 Mar 2026 |
Directors' Remuneration
| Item | Status |
|---|---|
Executive compensation | Not individually disclosed in sources reviewed. Korean rules require individual pay disclosure only above KRW 500M. |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
31 Mar 2025 | Shim Kyung-jae elected co-CEO | Post-acquisition; HLB-appointed management |
By Mar 2026 | Kim Jae-il described as CTO | — |
Major Shareholders
| Holder | Stake | Date | Source |
|---|---|---|---|
HLB Genex and related parties (incl. Chairman Jin Yang-gon) | 42.46% | Report filed 20 Aug 2026 (previously 42.70%) | DART large-shareholding report via StockHub |
HLB Genex (initial allotment) | 14.16% from a KRW 8bn subscription | March 2025 | Smart Today, 10 Mar 2025 |
HLB Group affiliates combined (initial) | 26.6% post-issue | March 2025 | Dealsite, 10 Mar 2025 |
Jin Yang-gon (HLB Group Chairman) | Bought about 22,000 shares, 12–19 Aug 2026 | Aug 2026 | Asia Economy, 20 Aug 2026 |
Shim Kyung-jae (CEO) | 22,470 shares after buying 2,170 | May 2026 | Asia Economy, 20 May 2026 |
Atinum Investment (historical VC) | 5.48% (down from 9.4%) | circa 2023 | IB Tomato. |
Minority shareholders (historical) | 61.25% | circa 2023 | IB Tomato |
Competitive Landscape
Key Competitors
| Competitor | Country | Overlap with HLB Pep | Relative positioning |
|---|---|---|---|
Bachem Holding AG | Switzerland | Peptide API CDMO (global leader) | Far larger scale; established FDA/EMA commercial supply |
PolyPeptide Group AG | Switzerland/Sweden | Peptide API CDMO; generic peptide APIs | Global scale; GLP-1 CDMO exposure |
CordenPharma | Germany/EU | Peptide CDMO | Global scale |
GL Biochem (Shanghai) | China | Custom, catalogue, pharmaceutical and cosmetic peptides | Direct product-line overlap (identified as a comparable by CB Insights); low-cost competitor |
Hybio Pharmaceutical | China | Generic peptide APIs | Competes in generic APIs; regulatory track record in US/EU |
WuXi TIDES (WuXi AppTec) | China | Peptide/oligo CDMO | Large-scale CDMO; subject to US geopolitical scrutiny |
AmbioPharm | US/China | Peptide API CDMO | Mid-size global CDMO |
CPC Scientific | US/China | Peptide API and custom peptides | Mid-size global supplier |
Peptron | Korea (KOSDAQ: 087010) | Peptide drug development and long-acting formulation | Korean peptide peer; drug developer rather than API CDMO |
Caregen | Korea (KOSDAQ: 214370) | Cosmetic and health peptides | Direct overlap with the LABSENN / cosmetic peptide strategy |
Peer Comparison FY2025
| Metric | HLB Pep (FY2025) | Bachem (FY2024) | PolyPeptide (FY2024) |
|---|---|---|---|
Revenue | KRW 5.0bn | About CHF 605M | About EUR 338M |
Revenue growth | -19.4% (derived) | — | — |
Operating margin | -146.0% (derived) | — | — |
Recent Developments
The register runs from April 2025 to October 2026, with the 31 March 2025 AGM included as an anchor.



